Hashimoto, Y., Kaji, A., Sakai, R., Osaka, T., Ushigome, E., Hamaguchi, M., Yamazaki, M., & Fukui, M
Ingredients ingredients Water, L-carnitine (9.2 ), fructose, acidic agent (citronic acid), zinc citrate, acid regulator (sodium hydroxide), preserving ff (potassium sorbate), sweetener (cyclamat, acesulfam k, saccharin), aroma
By the first quarter of 2026, tirzepatide had become the most frequently prescribed agent at roughly 4,700 prescriptions per 100,000 patients, and semaglutide had grown to around 3,900 per 100,000
According to FDA guidelines, these medications are approved for people with a: A body mass index (BMI) of 30 or higher BMI of 27 or higher who have at least one weight-related health condition, like type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, or cardiovascular disease These criteria help ensure that those most likely to benefit from treatment are prioritized
Thyroid considerations Animal studies with GLP-1 class agents have raised questions about thyroid C-cell tumours, which is why individuals with a history of medullary thyroid carcinoma or MEN2 are excluded from trials
Per HumeCare's own Medications Safety Information, compounded semaglutide and compounded tirzepatide are not the same as, equivalent to, or interchangeable with the FDA-approved branded products, and HumeCare's Terms require you to affirmatively acknowledge that distinction before receiving compounded medication
